Expertise in
5
conditions

Nicolas G. Mathieu

Grenoble, FR 
Expertise in
5
conditions
Grenoble, FR 

Overview

Nicolas Mathieu practices practicing medicine in Grenoble, France.

Mr. Mathieu is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Viral Gastroenteritis, Colitis, Crohn's Disease, and Hemorrhagic Proctocolitis.

He is actively involved in clinical research, co-authoring 35 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Grenoble, France
Other Locations
Echirolles, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

VeDOlizumab PERsistence in IBD Patients After Switching From Intravenous to Subcutaneous Administration : a Real-life Multicenter Study
VeDOlizumab PERsistence in IBD Patients After Switching From Intravenous to Subcutaneous Administration : a Real-life Multicenter Study
Enrollment Status: Unknown
Publish Date: July 22, 2024
Intervention Type: Drug
Impact of Anti-cytomegalovirus (Valganciclovir) Treatment in the Management of Relapsing Ulcerative Colitis (UC) Requiring Vedolizumab Therapy: a Randomized Clinical Trial Comparing a Strategy With or Without Antiviral Therapy.
Impact of Anti-cytomegalovirus (Valganciclovir) Treatment in the Management of Relapsing Ulcerative Colitis (UC) Requiring Vedolizumab Therapy: a Randomized Clinical Trial Comparing a Strategy With or Without Antiviral Therapy.
Enrollment Status: Terminated
Publish Date: April 10, 2024
Intervention Type: Drug
Study Drug: Valganciclovir
Study Phase: Phase 3
A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
Enrollment Status: Unknown
Publish Date: January 24, 2024
Intervention Type: Drug
A Multicentre Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative Colitis
A Multicentre Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative Colitis
Enrollment Status: Terminated
Publish Date: April 27, 2022
Intervention Type: Drug
Study Drug: GSK2831781
Study Phase: Phase 2
The Anti-inflammatory Effect of Vagus Nerve Stimulation (VNS): a New Approach in the Treatment of Crohn's Disease
The Anti-inflammatory Effect of Vagus Nerve Stimulation (VNS): a New Approach in the Treatment of Crohn's Disease
Enrollment Status: Terminated
Publish Date: May 03, 2018
Intervention Type: Device
Study Phase: Phase 3
View 4 Less Clinical Trials

35 Total Publications

Association between physical activity with disease activity and functional disability in patients with inflammatory bowel disease.
Association between physical activity with disease activity and functional disability in patients with inflammatory bowel disease.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: November 30, 2025

Frequently Asked Questions about Nicolas G. Mathieu

Is Nicolas G. Mathieu a top-rated expert for Viral Gastroenteritis?

MediFind is an objective health platform that identifies experts based on real-world data. Nicolas G. Mathieu is classified as an Distinguished expert for Viral Gastroenteritis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Nicolas G. Mathieu participate in research or clinical trials?

Yes. Nicolas G. Mathieu has published 35 articles and abstracts on conditions like Viral Gastroenteritis. You can view a list of Nicolas G. Mathieu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Mathieu's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile